Financial Daily from THE HINDU group of publications
Saturday, Feb 25, 2006
Financial Daily from THE HINDU group of publications Saturday, Feb 25, 2006 |
|
|
|
|
|
|
|
Corporate
-
Regulatory Bodies & Rulings USFDA nod for Aurobindo's Lisinopril Our Bureau
In a press release here on Friday, Aurobindo said Lisinopril is an angiotensin converting enzyme inhibitor used for controlling blood pressure, treating heart failure and preventing kidney damage in people with hypertension or diabetes. They also benefit patients, who have had heart attacks. According to the company, the market opportunity for the current approval is around $600 million. The product is manufactured at FDA approved multi purpose plant situated at Bachupally (Unit-III) in the city outskirts. The company said this cardio vascular system segment, generally referred as `prils', has a turnover of over $3.5 billion in the US market alone and is a key component of the company product portfolio. The Hyderabad-based Aurobindo Pharma has a comprehensive portfolio of over 10 prils in its pipeline and is vertically integrated, the release said.
More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|